Eli Lilly (LLY +1.06%), like many of its peers in the pharma industry, continues to battle the effects of the patent cliff. Two of its three top-selling products will lose exclusivity this year, but there is one jewel in its crown that investors don't need to worry about. In this video, health care analyst Max Macaluso dives into this drug's clinical use and growth.
Is This an Anchor for Eli Lilly Investors?
By Max Macaluso – Feb 11, 2013 at 6:30PM
NYSE: LLY
Eli Lilly
Market Cap
$769B
Today's Change
(1.06%) $8.61
Current Price
$821.04
Price as of October 23, 2025 at 4:00 PM ET
One top-selling drug that won't lose patent protection this year.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo